These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26622169)

  • 1. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.
    Smith MA; Lim A
    Drug Des Devel Ther; 2015; 9():6083-94. PubMed ID: 26622169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
    Deeks ED
    Drugs; 2015 Jun; 75(9):1027-38. PubMed ID: 26059288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
    Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
    Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
    Klibanov OM; Gale SE; Santevecchi B
    Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination.
    Gamal N; Andreone P
    Drugs Today (Barc); 2015 May; 51(5):303-14. PubMed ID: 26097903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
    King JR; Dutta S; Cohen D; Podsadecki TJ; Ding B; Awni WM; Menon RM
    Antimicrob Agents Chemother; 2016 Feb; 60(2):855-61. PubMed ID: 26596948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
    Feld JJ; Kowdley KV; Coakley E; Sigal S; Nelson DR; Crawford D; Weiland O; Aguilar H; Xiong J; Pilot-Matias T; DaSilva-Tillmann B; Larsen L; Podsadecki T; Bernstein B
    N Engl J Med; 2014 Apr; 370(17):1594-603. PubMed ID: 24720703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.
    Flisiak R; Flisiak-Jackiewicz M
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):559-567. PubMed ID: 28317409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
    Chen CH; Chen CH; Lin CL; Lin CY; Hu TH; Tung SY; Hsieh SY; Lu SN; Chien RN; Hung CH; Sheen IS
    Sci Rep; 2019 May; 9(1):7086. PubMed ID: 31068655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
    Andreone P; Colombo MG; Enejosa JV; Koksal I; Ferenci P; Maieron A; Müllhaupt B; Horsmans Y; Weiland O; Reesink HW; Rodrigues L; Hu YB; Podsadecki T; Bernstein B
    Gastroenterology; 2014 Aug; 147(2):359-365.e1. PubMed ID: 24818763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
    Trifan A; Stanciu C; Gheorghe L; Iacob S; Curescu M; Cijevschi Prelipcean C; Stefanescu G; Girleanu I; Chiriac S; Mihai C; Brisc C; Goldis A; Sporea I; Miftode E; Bataga S; Rogoveanu I; Preda C; Caruntu FA; Singeap AM
    Medicine (Baltimore); 2017 Dec; 96(50):e9271. PubMed ID: 29390377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
    Petta S; Marzioni M; Russo P; Aghemo A; Alberti A; Ascione A; Antinori A; Bruno R; Bruno S; Chirianni A; Gaeta GB; Giannini EG; Merli M; Messina V; Montilla S; Perno CF; Puoti M; Raimondo G; Rendina M; Silberstein FC; Villa E; Zignego AL; Pani L; Craxì A; ;
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):427-434. PubMed ID: 28497758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
    Isakov V; Paduta D; Viani RM; Enejosa JV; Pasechnikov V; Znoyko O; Ogurtsov P; Bogomolov PO; Maevskaya MV; Chen X; Shulman NS
    Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1073-1076. PubMed ID: 29762255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
    Cheng EY; Saab S; Holt CD; Busuttil RW
    Expert Opin Pharmacother; 2015; 16(18):2835-48. PubMed ID: 26646975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
    Khatri A; Mensing S; Podsadecki T; Awni W; Menon R; Dutta S
    Clin Drug Investig; 2016 Aug; 36(8):625-35. PubMed ID: 27153823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
    Hsieh YC; Jeng WJ; Huang CH; Teng W; Chen WT; Chen YC; Lin SM; Tai DI; Lin CY; Sheen IS
    PLoS One; 2018; 13(8):e0202777. PubMed ID: 30138456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial.
    Deutsch L; Houri I; Ben-Ari Z; Shlomai A; Veitsman E; Cohen-Ezra O; Issachar A; Mor O; Gozlan Y; Bruck R; Menachem Y; Zelber-Sagi S; Katchman H; Shibolet O
    BMC Infect Dis; 2020 Apr; 20(1):264. PubMed ID: 32245397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
    Poordad F; Sedghi S; Pockros PJ; Ravendhran N; Reindollar R; Lucey MR; Epstein M; Bank L; Bernstein D; Trinh R; Krishnan P; Polepally AR; Unnebrink K; Martinez M; Nelson DR
    J Viral Hepat; 2019 Aug; 26(8):1027-1030. PubMed ID: 30980576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
    Shiffman ML; Rustgi V; Bennett M; Forns X; Asselah T; Planas Vila R; Liu L; Pedrosa M; Moller J; Reau N
    Am J Gastroenterol; 2016 Jun; 111(6):845-51. PubMed ID: 27045929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
    Kowdley KV; Lawitz E; Poordad F; Cohen DE; Nelson DR; Zeuzem S; Everson GT; Kwo P; Foster GR; Sulkowski MS; Xie W; Pilot-Matias T; Liossis G; Larsen L; Khatri A; Podsadecki T; Bernstein B
    N Engl J Med; 2014 Jan; 370(3):222-32. PubMed ID: 24428468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.